Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22027296 | 0.91 | HDAC4 (0.51) | HDAC4ESR1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25975348 | 0.85 | MAPT (0.48) | HDAC4OPRL1CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL3553242 | 0.83 | HDAC4 (0.62) | HDAC4ALDH1A1SMN1; SMN2LMNAHSD11B1 | |
| SCHEMBL8572144 | 0.82 | HDAC4 (0.59) | HDAC4OPRL1ALDH1A1SMN1; SMN2P2RX7 | |
| SCHEMBL4711696 | 0.80 | ALDH1A1 (0.59) | CYP2C19CYP3A4ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL19537445 | 0.79 | LMNA (0.50) | HDAC4OPRL1ALDH1A1LMNAHSD11B1 | |
| SCHEMBL12120029 | 0.78 | ESR2 (0.45) | APPCYP2C19CYP3A4ESR1ESR2 | |
| SCHEMBL1335906 | 0.77 | ESR2 (0.48) | HDAC4APPCYP2C19CYP3A4ESR1 | |
| SCHEMBL1464894 | 0.77 | CA12 (0.44) | APPCYP2C19CYP3A4ESR1ESR2 | |
| SCHEMBL25460818 | 0.77 | HDAC4 (0.73) | HDAC4ALDH1A1SMN1; SMN2LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025050125-A1 | SUBSTITUTED BENZOXAZOLYLAMINO BENZOXAZOLES | IMMVENTION THERAPEUTIX (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1660504-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
| WO-2005021554-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | HDAC4 1249/4885OPRL1 2495/4885APP 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.